Pinnacle Wealth Management Advisory Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Pinnacle Wealth Management Advisory Group’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,445	Closed	-$9.19K	–	374
2024 Q4	$9.19K	Hold	12,445	–	–	﹤0.01%	356
2024 Q3	$19.5K	Hold	12,445	–	–	﹤0.01%	359
2024 Q2	$20.9K	Hold	12,445	–	–	﹤0.01%	349
2024 Q1	$29.9K	Hold	12,445	–	–	﹤0.01%	346
2023 Q4	$19K	Buy	12,445 +310	+3%	+$369	﹤0.01%	332
2023 Q3	$13.2K	Hold	12,135	–	–	﹤0.01%	313
2023 Q2	$27.8K	Buy	12,135 +750	+7%	+$1.99K	﹤0.01%	325
2023 Q1	$27.7K	Buy	11,385 +965	+9%	+$2.21K	﹤0.01%	313
2022 Q4	$19.9K	Buy	10,420 +280	+3%	+$596	﹤0.01%	296
2022 Q3	$24K	Buy	+10,140	New	+$28.1K	﹤0.01%	274

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Pinnacle Wealth Management Advisory Group's LXRX Position: Q1 2025 in Review

Pinnacle Wealth Management Advisory Group sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2025, closing a stake of 12,445 shares — an estimated $9.19K sold.

Pinnacle Wealth Management Advisory Group first reported a position in LXRX in Q3 2022 and held it in 10 quarters. The position peaked at $29.9K in Q1 2024. 127 funds tracked by Wall St. Rank hold LXRX as of Q1 2025.

Pinnacle Wealth Management Advisory Group reported no remaining Lexicon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Pinnacle Wealth Management Advisory Group sold 12,445 Lexicon Pharmaceuticals shares in Q1 2025, an estimated $9.19K.
Pinnacle Wealth Management Advisory Group first reported a position in Lexicon Pharmaceuticals in Q3 2022 and held it in 10 quarters.
Pinnacle Wealth Management Advisory Group's Lexicon Pharmaceuticals position peaked at $29.9K in Q1 2024.
127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2025.

Based on Pinnacle Wealth Management Advisory Group's 13F filing for Q1 2025, filed 7 May 2025.